dose of glutathione Detox from the Inside Out with IV Therapy High Dose Glutathione Protocol: Dosing

This trial, while not showing superiority of JTA-004 over placebo in the overall population, provides highly valuable insights into clinical trial design, placebo responses, and the potential need for better patient stratification in osteoarthritis research

These are the brand's stated intended use cases, not clinical indications.* These statements have not been evaluated by the FDA

PL BioScience has advanced an oral BPC-157 formulation (designated PL-10) to Phase II clinical trials for inflammatory bowel disease representing the most clinically advanced human development of oral BPC-157 to date.3 Human peer-reviewed results from these trials are pending, but the preclinical rationale is strong

The approval is based on a pair of multicenter, placebo-controlled 12-week studies that showed significantly more patients taking Eohilia achieved histologic remission vs

A 2.5 mg dose now equals 1.0 mL

If BPC-157's preclinical mechanisms translate to humans, it could address reflux pathology in ways existing drugs don't